Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 27;19(3):664–675. doi: 10.1111/jcmm.12382

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig 1 — ECGT with IL12 pDNA is equally effective with gemcitabine or bleomycin. Analysing all treatment cycles with IL12 pDNA and either bleomycin (IL12 + blm) or gemcitabine (IL12 + gem) in squamous cell carcinoma (A, SCC, n + 9, 10), plasmacytoma (B, PC, n + 2, 3) and sarcoma (C, Sarc, n + 5, 4) reveals that ECGT is equally effective with blm or gem. (D) Comparison of all tumour histotypes shows that sarcomas do not respond to ECGT while PC and SCC are very responsive. (E) ECGT treatments extends survival compared to non-surgical standard treatments. Survival curve comparing ECGT (n + 16) and non-surgical standard treatments in subjects with complete records at the clinical trial host site. Error bars represent SEM.